Kast Stephanie, Jakob Franz, Kohl Matthias, von Stengel Simon, Kerschan-Schindl Katharina, Lange Uwe, Thomasius Friederike, Kemmler Wolfgang
Institute of Radiology, FAU-Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany.
Bernhard-Heine-Centrum für Bewegungsforschung, University of Würzburg, Würzburg, Germany.
Rheumatol Adv Pract. 2023 Feb 6;7(1):rkad019. doi: 10.1093/rap/rkad019. eCollection 2023.
Due to their pronounced anti-inflammatory and immunosuppressive effects, glucocorticoids (GCs) are widely used in inflammatory conditions and organ transplants. Unfortunately, GC-induced osteoporosis is one of the most common causes of secondary osteoporosis. The aim of the present systematic review and meta-analysis was to determine the effect of exercise added to GC therapy on BMD at the lumbar spine or femoral neck in people on GC therapy.
A systematic literature search of five electronic databases included controlled trials with a duration of >6 months and at least two study arms [glucocorticoids (GCs) and GCs and exercise (GC + EX)] were conducted up to 20 September 2022. Studies involving other pharmaceutical therapies with relevant effects on bone metabolism were excluded. We applied the inverse heterogeneity model. Outcome measures were standardized mean differences (SMDs) with 95% CIs for BMD changes at the lumbar spine (LS) and femoral neck (FN).
We identified three eligible trials with a total of 62 participants. In summary, the GC + EX intervention indicated statistically significantly higher SMDs for LS-BMD [SMD 1.50 (95% CI 0.23, 2.77)] but not for FN-BMD [0.64 (95% CI -0.89, 2.17)] compared with GC treatment alone. We observed substantial heterogeneity (LS-BMD = 71%, FN-BMD = 78%) between the study results.
Although more well-designed exercise studies are needed to address the issue of exercise effects on GC-induced osteoporosis (GIOP) in more detail, upcoming guidelines should pay more attention to the aspect of exercise for bone strengthening in GIOP.
PROSPERO: CRD42022308155.
由于具有显著的抗炎和免疫抑制作用,糖皮质激素(GCs)被广泛用于治疗炎症性疾病和器官移植。不幸的是,GC诱导的骨质疏松症是继发性骨质疏松症最常见的病因之一。本系统评价和荟萃分析的目的是确定在接受GC治疗的人群中,运动联合GC治疗对腰椎或股骨颈骨密度(BMD)的影响。
对五个电子数据库进行系统文献检索,纳入持续时间超过6个月且至少有两个研究组[糖皮质激素(GCs)组和糖皮质激素与运动联合组(GC + EX)]的对照试验,检索截至2022年9月20日。排除涉及对骨代谢有相关影响的其他药物治疗的研究。我们应用了逆异质性模型。结局指标为腰椎(LS)和股骨颈(FN)BMD变化的标准化均数差(SMD)及95%可信区间(CI)。
我们确定了三项符合条件的试验,共62名参与者。总体而言,与单独使用GC治疗相比,GC + EX干预组的LS-BMD标准化均数差在统计学上显著更高[SMD 1.50(95%CI 0.23,2.77)],但FN-BMD标准化均数差未显示差异[0.64(95%CI -0.89,2.17)]。我们观察到研究结果之间存在显著异质性(LS-BMD I² = 71%,FN-BMD I² = 78%)。
尽管需要更多设计良好的运动研究来更详细地解决运动对GC诱导的骨质疏松症(GIOP)影响的问题,但即将出台的指南应更多关注GIOP中通过运动增强骨骼这一方面。
PROSPERO:CRD42022308155。